Acetyl Tetrapeptide-5 (Eyeseryl): What the Research Actually Shows

Educational Notice

This article is written for researchers, formulators, clinicians, and informed consumers seeking to understand the published evidence on acetyl tetrapeptide-5 (Eyeseryl). It is not medical advice, a treatment recommendation, or an endorsement of any product. Acetyl tetrapeptide-5 is a cosmetic ingredient — not a pharmaceutical drug — and is not evaluated by the FDA for safety or efficacy. The periorbital area requires particular care with any topical or invasive treatment. Consult a qualified dermatologist or healthcare professional before making decisions about your skin health, especially regarding the eye area.

A Comprehensive Evidence Review for Researchers, Formulators, and Informed Consumers

Acetyl tetrapeptide-5 — tradename Eyeseryl® — occupies a distinct niche in the cosmetic peptide landscape. Every other compound in the Cluster G group targets either neuromuscular contraction (argireline, Syn-Ake, Leuphasyl, Snap-8), collagen synthesis (original Matrixyl, Matrixyl 3000 components), or inflammation (palmitoyl tetrapeptide-7). Acetyl tetrapeptide-5 targets periorbital edema — under-eye puffiness — through a mechanism that is fundamentally different from all of them: reducing capillary permeability and inhibiting glycation in the delicate skin surrounding the eye.

Under-eye puffiness is one of the most searched cosmetic concerns on the internet and one of the least effectively addressed by topical products. The causes are multiple and only partially related to skin or tissue chemistry — fluid accumulation from sleep position, lymphatic drainage inefficiency, fat pad herniation through weakened orbital septum, and genuine skin laxity all contribute, and no topical ingredient can address the structural causes. Acetyl tetrapeptide-5 addresses a specific subset of the problem: the edema component driven by excessive capillary fluid leakage and glycation-related tissue changes in the periorbital dermis.

The evidence behind it includes a Lipotec-sponsored clinical study reporting a 70% reduction in under-eye puffiness that appears across product marketing with the same lack of context that characterizes the “36% wrinkle reduction” figure for Matrixyl 3000. That number comes from one small study, at one concentration, in one formulation, over one time period. This article examines what was actually measured, what the mechanisms are, and what the honest evidence picture looks like for each delivery route — including a specific assessment of why the periorbital area requires extra caution for microneedling and injection.

Quick Facts

INCI Name

Acetyl Tetrapeptide-5

Mechanism Class

Anti-edema signal peptide — capillary permeability reduction + anti-glycation

Evidence Tier

Pilot / Limited Human Data

Regulatory Status

Cosmetic ingredient — not a drug. No FDA approval or evaluation required.

WADA Status

Not prohibited

Typical Topical Concentration

5% in published studies; 2–5% in commercial eye area products

Molecular Weight

~605 Da — above the 500 Da passive penetration threshold; acetyl group improves lipid solubility

Tradename

Eyeseryl® (Lipotec/Lubrizol)

The research moves fast. We read all of it so you don’t have to.

New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.

Subscribe to Peptidings Weekly

What Is Acetyl Tetrapeptide-5?

Acetyl tetrapeptide-5 (Eyeseryl®) is a synthetic tetrapeptide developed by Lipotec (now Lubrizol Advanced Materials) specifically for application in the periorbital area — the delicate skin around the eyes. Its INCI name is acetyl tetrapeptide-5, and its sequence is acetyl-β-Ala-His-Ser-His-NH₂ (Ac-βAHsH-NH₂), a modified tetrapeptide incorporating β-alanine rather than standard α-alanine, which contributes to its stability and receptor-binding characteristics.

Unlike the other Cluster G peptides, acetyl tetrapeptide-5 was designed specifically for the under-eye area with a dual-mechanism approach: reducing capillary permeability to decrease fluid leakage into the periorbital tissue (the primary driver of the edema component of under-eye puffiness), and inhibiting glycation — the non-enzymatic reaction between sugars and proteins that cross-links and stiffens the extracellular matrix, contributing to the structural changes that make the periorbital skin appear aged and puffy.

Origins and Development

Eyeseryl was developed by Lipotec, the same Barcelona-based cosmetic ingredient company that developed Argireline. Like Argireline, it was designed to address a specific cosmetic concern — under-eye puffiness — with a mechanism grounded in identifiable biology. The periorbital area presents a distinct formulation challenge: the skin is thinner than facial skin (approximately 0.5 mm versus 2 mm elsewhere), more vascularized, and in close proximity to the eye itself, constraining the types of actives and concentrations that can be safely used.

Lipotec conducted the primary clinical study for Eyeseryl internally and published the findings through technical documentation and conference presentations rather than as a standalone peer-reviewed journal article indexed in PubMed. The ingredient was subsequently acquired into the Lubrizol portfolio alongside Argireline when Lubrizol acquired Lipotec. It remains available as a proprietary ingredient to licensed cosmetic manufacturers.

Under-Eye Puffiness: Causes and What Eyeseryl Targets

Under-eye puffiness has multiple contributing causes, and understanding which of them topical ingredients can realistically address is essential to honest evaluation of any under-eye product claim.

Cause Mechanism Addressable by Eyeseryl?
Periorbital edema (fluid accumulation) Excess capillary permeability allows plasma fluid to leak into periorbital tissue; impaired lymphatic drainage compounds the effect Partially — capillary permeability reduction is the primary Eyeseryl mechanism
Glycation-related tissue stiffening AGE cross-linking of collagen and elastin reduces tissue elasticity, worsening the appearance of fluid accumulation Yes — anti-glycation is the secondary Eyeseryl mechanism
Sleep position / gravity-dependent edema Fluid accumulates during sleep when horizontal; typically resolves within hours of waking No — positional, not chemical
Orbital fat pad herniation Age-related weakening of the orbital septum allows periorbital fat to migrate forward; creates structural bulge No — structural, requires surgical correction
Skin laxity and collagen loss Loss of skin elasticity amplifies the visible impact of fat and fluid changes No direct mechanism — other peptides (GHK-Cu, Matrixyl) are more relevant for this component
Allergic or inflammatory edema Mast cell degranulation and histamine release causes acute periorbital edema; can be chronic with environmental allergens No — requires antihistamine or anti-inflammatory intervention

Plain English

Under-eye bags have several different causes. Eyeseryl addresses one of them — the fluid-leakage component — and may help with glycation-related tissue changes. If your under-eye puffiness is mainly structural (fat herniation), related to sleep position, or driven by allergies, a topical peptide will not meaningfully help regardless of how good the clinical data is for the capillary permeability mechanism.

Mechanism of Action

Capillary Permeability Reduction

Capillary walls in the periorbital area are maintained by tight junctions between endothelial cells and by the integrity of the basement membrane. When these barriers are compromised — by UV damage, inflammation, age-related endothelial dysfunction, or elevated vascular endothelial growth factor (VEGF) activity — plasma fluid and proteins leak from the capillary lumen into the surrounding interstitial tissue. This fluid accumulation in the periorbital dermis produces the puffiness that patients and consumers identify as under-eye bags.

Acetyl tetrapeptide-5 is proposed to reduce this capillary permeability by interacting with adhesion molecules on the endothelial cell surface, strengthening tight junction integrity and reducing the rate of plasma fluid extravasation into periorbital tissue. Lipotec’s technical data demonstrates reduced albumin leakage from capillary-mimicking models treated with acetyl tetrapeptide-5 in vitro. This is the mechanistic foundation for the anti-edema claim.

Plain English

Tiny blood vessels around the eye can become leaky, allowing fluid to seep into the surrounding tissue and accumulate as puffiness. Acetyl tetrapeptide-5 is designed to seal those leaks by strengthening the vessel walls. The mechanism works in laboratory models. Whether a topically applied peptide penetrates periorbital skin to reach those vessels in meaningful concentrations is the key unanswered question.

Anti-Glycation Activity

Glycation is the non-enzymatic reaction between reducing sugars (primarily glucose) and the free amino groups of proteins — collagen, elastin, and other structural proteins — to form advanced glycation end-products (AGEs). AGEs cross-link proteins, reducing their elasticity and promoting tissue stiffness. In periorbital skin, AGE accumulation in collagen and elastin contributes to the loss of tissue resilience that makes fluid accumulation appear worse — stiffer, less elastic tissue cannot accommodate fluid as effectively as healthy elastic tissue, making even small amounts of edema more visually prominent.

Acetyl tetrapeptide-5 contains histidine residues, which can chelate transition metal ions (particularly copper and iron) that catalyze the free radical reactions involved in AGE formation. By chelating these metal ions, the peptide may reduce the rate of glycation-driven protein cross-linking in the periorbital dermis. This is a dual protective mechanism: reducing both the fluid accumulation itself and the tissue stiffness that amplifies its appearance.

Plain English

Sugar molecules in the body slowly stick to skin proteins and stiffen them — a process called glycation that accumulates over years and makes skin less elastic. Acetyl tetrapeptide-5 has chemistry that may slow this process around the eyes. Even a modest reduction in tissue stiffening could help the skin cope better with any fluid that does accumulate — making puffiness less visible even if the amount of fluid hasn’t changed much.

Key Research Areas and Studies

The Primary Lipotec Clinical Study

The clinical evidence for acetyl tetrapeptide-5 centers on a Lipotec-sponsored study of 20 women (ages 18–45) with noticeable under-eye puffiness who applied a 5% Eyeseryl eye contour cream twice daily for 60 days. Periorbital puffiness was assessed using optical profilometry — a surface topography measurement — at baseline, 30 days, and 60 days. The study reported a 70% reduction in under-eye puffiness volume at 60 days in the Eyeseryl arm versus a vehicle control. A self-assessment component showed 95% of participants reporting improvement in under-eye appearance.

Several contextual points are essential for interpreting this finding. The study enrolled only 20 women. Participants were selected for having noticeable under-eye puffiness — a population in which the edema component (potentially addressable by the mechanism) may be disproportionately represented versus structural fat herniation (not addressable). The age range of 18–45 is younger than most anti-aging clinical studies, potentially selecting for participants whose puffiness has a larger reversible edema component than older participants would. The 70% figure represents a change in profilometry measurement of the periorbital surface — not a direct measure of fluid volume or capillary permeability. And the full study methodology and raw data are in Lipotec’s technical documentation, not in a peer-reviewed journal indexed in PubMed.

Evidence note: The “70% reduction in under-eye puffiness” figure appears across thousands of product listings and editorial pieces about Eyeseryl. It traces to a single manufacturer-sponsored study of 20 women, selected for having visible puffiness, ages 18–45 — a population likely to have a higher proportion of reversible edema than a general aging population. The profilometry measure is valid; the generalizability to the broader population of people using under-eye products is uncertain.

In Vitro Studies

Lipotec’s technical data includes in vitro studies demonstrating reduced albumin leakage in an endothelial permeability model, reduced AGE formation in a glycation assay, and reduced VEGF-stimulated endothelial hyperpermeability. These mechanistic studies confirm that the compound does what the mechanism proposes at the tested concentrations in laboratory conditions. As with all cosmetic peptide in vitro data, the translation from isolated endothelial cells in culture to intact periorbital skin in living humans involves multiple additional variables — penetration through skin, protein binding, metabolic stability — that are not captured in cell-free or cell culture models.

Independent Research

No independent peer-reviewed clinical studies of acetyl tetrapeptide-5 have been identified in PubMed-indexed literature. The ingredient appears in review articles on cosmetic peptides (Gorouhi and Maibach 2009; Schagen 2017) with brief mentions, but without independent clinical data beyond the Lipotec study. The anti-glycation mechanism is supported by the broader literature on glycation and advanced glycation end-products in skin aging — this is a well-characterized aging process — but the specific contribution of topically applied acetyl tetrapeptide-5 to reducing periorbital glycation in living human skin is not independently established.

Common Claims versus Current Evidence

Claim What the Evidence Shows Verdict
“Reduces under-eye puffiness by 70%” Sourced from Lipotec study — 20 women, 5%, 60 days, profilometry. Real measurement. Study population may over-represent the reversible edema component. Not in a peer-reviewed PubMed-indexed journal. Not independently replicated. Technically sourced; study population and design context always omitted
“Works for all types of under-eye bags” Acetyl tetrapeptide-5 addresses the capillary permeability (edema) component of puffiness and may reduce glycation-related tissue stiffening. It cannot address structural fat herniation, positional fluid, or allergic edema — which together account for a significant proportion of under-eye puffiness in the general population. Incorrect — mechanism-specific; not universal
“Safe for injection near the eye” No published injection data. The periorbital area is one of the highest-risk anatomical regions for any injection procedure — proximity to the orbit, ophthalmic artery, and critical neural structures means injection errors carry risk of severe adverse events including vision loss. Cosmetic-grade material is not manufactured to injectable standards. No evidence; periorbital injection is high-risk regardless of compound
“Anti-glycation equals anti-aging” Glycation is one contributor to skin aging — reducing it is mechanistically meaningful. Anti-glycation activity is one mechanism among many addressing skin aging. In isolation, anti-glycation without collagen stimulation or MMP suppression addresses only part of the aging process. Partially supported — valid mechanism, incomplete picture

The research moves fast. We read all of it so you don’t have to.

New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.

Subscribe to Peptidings Weekly

The Human Evidence Landscape

Acetyl tetrapeptide-5’s human evidence picture is structurally similar to other Cluster G compounds — one small manufacturer-sponsored clinical study, not published as a standalone peer-reviewed article in PubMed, with effect sizes that appear in marketing without the full methodological context. The 70% reduction figure is numerically impressive and the study design (profilometry, vehicle control, 60-day duration) is reasonable. The sample of 20 women, manufacturer association, and publication format are the primary limitations.

One important contextual factor for acetyl tetrapeptide-5 specifically: the under-eye puffiness market is particularly prone to placebo effects and subjective assessment confounds. Under-eye appearance changes dramatically with sleep quality, hydration status, salt intake, and time of day. A 60-day study measuring subjective and profilometry-based puffiness must carefully control for these variables — and the published summary of the Lipotec study does not provide sufficient methodological detail to confirm that all relevant confounders were adequately managed.

The self-assessment component — 95% of participants reporting improvement — should be treated with particular caution. Self-assessment in open-label or single-blind studies of appearance-focused interventions consistently over-reports positive outcomes due to expectation bias, social desirability, and the inherent variability of the appearance feature being assessed. The profilometry data is a more objective measure, but its clinical meaningfulness depends on the magnitude of measurement change relative to the detection threshold and day-to-day natural variability in periorbital surface topology.

Safety, Risks, and Limitations

Topical Safety

Acetyl tetrapeptide-5 has a good topical safety record in cosmetic use. The clinical study documented no significant adverse events. Contact sensitization is rare. The periorbital skin is thinner and more sensitive than other facial skin, making formulation considerations — preservative selection, fragrance avoidance, pH optimization — more important for eye-area products. The ingredient itself is well-tolerated, but the formulation context matters more in the periorbital area than elsewhere.

Microneedling Safety — Periorbital Considerations

Microneedling in the periorbital area — which some community members and practitioners use with acetyl tetrapeptide-5 solution — carries substantially higher risks than facial microneedling elsewhere. The periorbital skin is the thinnest on the face. The eye itself is in proximity: standard microneedling depths of 0.5–1.5 mm in the infraorbital area approach the orbital rim and risk mechanical injury to periorbital structures. The infraorbital nerve provides sensation to the lower eyelid, cheek, and upper lip — mechanical trauma from microneedling near the orbital rim risks transient or persistent neurosensory effects.

Professional microneedling practitioners who work in the periorbital area typically use shallow depths (0.25 mm or less), different device types than standard dermarollers, and appropriate technique modifications for the delicate periorbital anatomy. The self-experimentation community’s standard microneedling protocols — designed for facial skin at 0.5–1.5 mm depth — are not appropriate for the periorbital area without significant modification. No published clinical trial of acetyl tetrapeptide-5 delivered via microneedling exists.

Safety Note — Periorbital Microneedling

Standard self-experimentation microneedling protocols are not appropriate for the periorbital area. The skin is thinner, the orbit is in proximity, the infraorbital nerve is at risk, and the consequences of technique errors are more serious than in other facial areas. If using microneedling near the eye, depth should be 0.25 mm or less, technique must be appropriate for the anatomy, and cosmetic-grade peptide solutions introduce the same sterility concerns as any other microneedling application. This is a procedure best left to practitioners with appropriate periorbital anatomy training.

Subcutaneous Injection Safety — Periorbital

Subcutaneous injection of any compound in the periorbital area is among the highest-risk cosmetic procedures that exist outside surgical settings. The periorbital region is richly vascularized by branches of the ophthalmic artery (supraorbital, supratrochlear, angular arteries) and the infraorbital artery. Intravascular injection or vascular compression in this region — even with filler materials injected by trained practitioners — has caused vision loss, stroke, and blindness through retrograde arterial embolization to the ophthalmic and central retinal arteries.

For a cosmetic-grade peptide with no published injection data, no injectable sterility standard, and no pharmacological rationale for SC delivery over topical application, injection near the eye has no defensible justification. This is not a pharmacological argument about mechanism or evidence — it is a direct anatomical safety concern that exists regardless of the compound being injected.

Safety Note — Periorbital Injection

Injection of any material — sterile or not, pharmaceutical or cosmetic — near the orbit carries risks of serious adverse events including vision loss through ophthalmic artery compromise. This risk is not specific to acetyl tetrapeptide-5; it is inherent to the anatomy of the periorbital region. Even experienced practitioners with sterile filler materials have caused blindness from periorbital injection technique errors. Self-injection of cosmetic-grade peptide solutions near the eye is not a practice with any defensible risk-benefit ratio.

Legal and Regulatory Status

Acetyl tetrapeptide-5 is a cosmetic ingredient regulated under standard cosmetic frameworks in the US and EU. No FDA pre-market approval is required. In the EU, Regulation EC 1223/2009 applies. For eye-area cosmetics specifically, regulatory frameworks in both jurisdictions apply enhanced scrutiny to safety assessment due to proximity to the eye — but this applies to the full formulation, not specifically to acetyl tetrapeptide-5 as a raw ingredient.

Eyeseryl® is a proprietary tradename of Lubrizol Advanced Materials (via Lipotec acquisition). Generic acetyl tetrapeptide-5 is available from other suppliers. Permitted in cosmetic formulations without specific concentration restrictions in either jurisdiction, though eye-area formulations require appropriate ophthalmological safety assessment. WADA status: not prohibited.

Research Protocols and Formulation Considerations

Concentration: The clinical study used 5% acetyl tetrapeptide-5. Lipotec recommends 3–5% for eye contour formulations. Commercial products vary — those that disclose concentration typically list 2–5%. Below 2% is likely substantially under-dosed relative to the clinical evidence anchor.

Eye-area formulation requirements: Eye-area cosmetics require particular care in formulation. Preservatives must be ophthalmologically tested and appropriate for proximity to the eye (no high-concentration phenoxyethanol, no formaldehyde-releasing preservatives). Fragrance should be avoided or minimized. pH should be maintained within physiological ocular ranges (6.5–7.5). The periorbital skin’s thinner barrier means penetration enhancers that would be acceptable elsewhere may cause sensory irritation near the eye.

Combination with other anti-puffiness actives: Caffeine is one of the most widely used anti-puffiness cosmetic actives — it acts as a phosphodiesterase inhibitor, increasing cyclic AMP in vascular smooth muscle cells and promoting vasoconstriction. Its mechanism is complementary to acetyl tetrapeptide-5’s capillary permeability approach. Combining both addresses puffiness via vasoconstriction (caffeine) and permeability reduction (acetyl tetrapeptide-5). Hesperidin methyl chalcone is another frequently combined active with capillary-strengthening effects. No published study of these combinations specifically with acetyl tetrapeptide-5 exists.

Dosing and Delivery: What the Research Shows

Topical Application

The Lipotec clinical study applied 5% acetyl tetrapeptide-5 twice daily for 60 days to the periorbital area. This is the sole evidence anchor. The thinner periorbital skin (approximately 0.5 mm versus 2 mm elsewhere on the face) is more permeable than other facial skin — the penetration challenge is lower than for the same ingredient applied to thicker facial skin. This is one reason eye-area active concentrations are sometimes lower than the same compound used elsewhere; the thinner barrier means more reaches the target tissue per unit of applied concentration.

Application technique matters in the periorbital area: gentle patting rather than rubbing, applied from the outer orbital rim inward along the orbital bone, avoiding direct contact with the eye. Morning application may be more beneficial than evening for edema-targeting ingredients, as periorbital edema is typically greatest upon waking after overnight fluid accumulation — though the evidence base for optimizing application timing specific to this compound is entirely absent.

Microneedling / Stamping

Microneedling in the periorbital area with acetyl tetrapeptide-5 is practiced in some community and clinical settings. No published trial data exists. Given the target structure — capillary endothelium, which is at the dermal vasculature level rather than the muscle depth — microneedling at very shallow depths (0.25 mm) that access the dermis without approaching the orbital rim may theoretically improve dermal delivery. The periorbital anatomy safety considerations described in the safety section apply in full. Standard community microneedling protocols are not appropriate. The thinner periorbital skin means even shallow channels penetrate proportionally deeper relative to the tissue than equivalent needle depths in thicker facial skin.

Subcutaneous Injection

SC injection near the periorbital area is not a practice with a defensible risk-benefit ratio for any cosmetic-grade peptide at any concentration. This is not primarily a pharmacological argument — it is an anatomical safety argument. The periorbital vascular anatomy places the ophthalmic artery system in direct proximity to any injection in this region. The risk of inadvertent intravascular injection or vascular compression with retrograde embolization to the ophthalmic artery exists regardless of what compound is being injected. The absence of published safety data for acetyl tetrapeptide-5 injection is one additional concern on top of the fundamental anatomical risk.

Delivery Routes in Self-Experimentation Communities

Route Community Use Evidence Key Risks
Topical eye contour cream/gel Common — standard cosmetic use; widely available in commercial eye products Lipotec study (20 women, 5%, 60 days); in vitro capillary permeability and anti-glycation data Low — good topical safety record; eye-area formulation quality matters more than elsewhere
Microneedling / stamping (periorbital) Some community practice; less common than facial microneedling elsewhere No published trials; periorbital anatomy raises distinct risk profile versus facial microneedling Higher — thinner skin, orbital rim proximity, infraorbital nerve risk; standard depth protocols inappropriate; sterility of source material
SC injection (periorbital) Rare — some community reports; generally recognized as high-risk even within self-experimentation communities No published data Highest — ophthalmic artery proximity; risk of vision loss from vascular compromise; non-sterile source material; no pharmacological rationale over topical application

Community use of acetyl tetrapeptide-5 is predominantly topical, typically as a component of commercial or DIY eye serums at 2–5% concentration. The self-experimentation peptide community’s awareness of the periorbital injection risk is generally higher for this compound than for others — under-eye injection is one area where even enthusiastic self-experimenters tend to exercise caution, likely because the anatomical proximity of the eye to injection site is viscerally apparent in a way that subcutaneous facial or abdominal injection is not. Topical application at appropriate concentrations in properly formulated eye-area products remains the evidence-supported and practically appropriate route.

Frequently Asked Questions

Q: What is Eyeseryl (acetyl tetrapeptide-5) and how does it work?

A: Eyeseryl (INCI: acetyl tetrapeptide-5) is a synthetic tetrapeptide developed by Lipotec/Lubrizol specifically for the periorbital area. It works through two complementary mechanisms: reducing capillary permeability — the tendency of small blood vessels around the eye to leak fluid into surrounding tissue and cause puffiness — and inhibiting glycation, the process by which sugars chemically cross-link skin proteins and stiffen the tissue. It is the only Cluster G compound targeting periorbital edema rather than collagen synthesis or muscle relaxation.

Q: Does Eyeseryl actually work for under-eye bags?

A: It depends on what's causing your under-eye bags. Eyeseryl addresses the capillary permeability (fluid leakage) and glycation components of puffiness. It cannot address fat pad herniation through the orbital septum (a structural issue requiring surgical correction), positional fluid from sleep, or allergic edema. The primary clinical study — 20 women, 5% formulation, 60 days — reported 70% reduction in puffiness by profilometry. This is a small, manufacturer-sponsored study whose population may over-represent the reversible edema component. If your puffiness is mainly structural, Eyeseryl is unlikely to make a meaningful difference regardless of evidence quality.

Q: What concentration of Eyeseryl should I look for in a product?

A: The clinical study used 5%. Lipotec recommends 3–5% for eye contour formulations. Look for products that list acetyl tetrapeptide-5 in the first third of the INCI list — position in the INCI list broadly indicates relative concentration. Products below 2% are likely significantly under-dosed relative to the studied concentration.

Q: What is glycation and why does it matter for under-eye skin?

A: Glycation is the non-enzymatic reaction where sugar molecules attach to and cross-link proteins — including collagen and elastin — forming advanced glycation end-products (AGEs). This process stiffens the extracellular matrix over time, reducing skin elasticity and resilience. In the periorbital area, AGE accumulation means tissue cannot accommodate fluid accumulation as effectively, making even small amounts of edema appear more prominent. Acetyl tetrapeptide-5 contains histidine residues that may chelate the metal ions catalyzing glycation reactions, slowing AGE formation in periorbital tissue.

Q: Is it safe to microneedle with Eyeseryl around the eyes?

A: The periorbital area requires specific technique modification for microneedling — standard community protocols (0.5–1.5 mm depth) are not appropriate. The periorbital skin is thinner (approximately 0.5 mm versus 2 mm elsewhere), the orbital rim is in proximity, and the infraorbital nerve is at risk from mechanical trauma. If microneedling near the eye is used at all, depth should be 0.25 mm or less, with technique appropriate to the anatomy. This is best performed by practitioners familiar with periorbital anatomy, not via standard home microneedling devices. Sterility of any cosmetic-grade solution used remains the primary risk for all microneedling applications.

Q: Is it safe to inject Eyeseryl near the eyes?

A: No — and this is primarily an anatomical safety issue, not a peptide-specific one. The periorbital region is richly vascularized by branches of the ophthalmic artery. Injection of any material near the orbit carries risk of inadvertent intravascular injection or vascular compression with retrograde embolization to the ophthalmic artery — a mechanism that has caused vision loss and blindness even when performed by trained practitioners with sterile pharmaceutical-grade fillers. For a cosmetic-grade peptide with no published injection data and no pharmacological rationale over topical application, periorbital injection has no defensible risk-benefit ratio.

Q: What can I combine with Eyeseryl for better under-eye results?

A: For the edema component, caffeine (vasoconstriction, acutely reduces visible puffiness) and hesperidin methyl chalcone (capillary-strengthening flavonoid) are commonly combined with Eyeseryl on complementary mechanistic grounds. For the tissue laxity and collagen-loss components of under-eye aging — which Eyeseryl does not address — GHK-Cu and Matrixyl 3000 are more relevant. For expression lines in the periorbital area (crow's feet), argireline and Syn-Ake target the NMJ mechanism. A comprehensive eye-area formulation often combines multiple mechanisms targeting these different aspects of periorbital aging simultaneously.

Q: How long does Eyeseryl take to work?

A: The clinical study measured outcomes at 30 and 60 days with twice-daily application, with greater improvement at 60 days. Edema reduction from capillary permeability improvement may be somewhat more rapid than structural collagen changes — but the 60-day study duration suggests the full effect takes at least two months to develop. Morning application may be most relevant since periorbital edema is typically greatest upon waking. Individual results will vary significantly depending on the underlying cause of puffiness.

Acetyl tetrapeptide-5 is the only compound in Cluster G targeting periorbital edema specifically. Its dual mechanism — capillary permeability reduction and anti-glycation — is distinct from every other compound in the group. Non-peptide actives commonly combined with it in eye contour formulations include caffeine (vasoconstriction, reduces visible puffiness acutely) and hesperidin methyl chalcone (capillary-strengthening flavonoid). For the collagen and tissue-laxity components of under-eye aging, GHK-Cu and Matrixyl 3000 are the more relevant compounds. The table below shows all twelve compounds in the Skin & Cosmetic cluster for direct comparison.

Edit
Compound Type Primary Target Half-Life FDA Status WADA Status Evidence Tier Skin Target / Mechanism Typical Concentration Route Key Differentiator
Argireline (Acetyl Hexapeptide-3) Synthetic hexapeptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2, SNAP-25 modulator) SNARE complex disruption / Botox-like wrinkle reduction (proposed) ~2–4 hours (topical; serum stability uncertain) Not FDA-approved (cosmetic ingredient, GRAS status for topical use) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Expression wrinkles (periorbital, forehead); muscle contraction inhibition (proposed topical analog to botulinum toxin mechanism) Typically 3–5% in cosmetic formulations Topical (creams, serums, cosmetics) Botox alternative for topical use. Synthetic SNARE inhibitor design. Limited published clinical efficacy vs. marketing claims
Matrixyl (Palmitoyl Pentapeptide-4) Synthetic pentapeptide conjugated to palmitic acid (Pal-GVQPR, collagen-stimulating) Procollagen upregulation (TGF-β pathway proposed); collagen I/III synthesis ~1–3 hours (topical) Not FDA-approved (cosmetic ingredient) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Dermal collagen remodeling; fine-line reduction; skin firmness (proposed) Typically 1–3% in cosmetic formulations Topical (creams, anti-aging serums) First-generation palmitoyl peptide anti-aging cosmetic. Synthetic TGF-β mimic. Limited independent clinical validation
Matrixyl 3000 (Palmitoyl Tripeptide-1 + Palmitoyl Tetrapeptide-7 Blend) Synthetic blend of two palmitoyl peptides (Pal-GHK + Pal-GHKGQ, synergistic collagen/elastin remodeling) Dual collagen + elastin upregulation (proposed; broader TGF-β pathway activation) ~1–3 hours (topical) Not FDA-approved (cosmetic ingredient blend) Not WADA-listed (topical cosmetic peptide blend) Tier 4 — Preclinical Only Dermal collagen and elastin remodeling; wrinkle depth and skin texture improvement (proposed) Typically 1–3% in cosmetic formulations (as synergistic blend) Topical (creams, serums, moisturizers) Second-generation peptide blend (Matrixyl + Palmitoyl Tetrapeptide-7). Synergistic formulation strategy. Limited peer-review studies
Snap-8 (Acetyl Octapeptide-3) Synthetic octapeptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-Gly-Gly-NH2, extended Argireline analog) Extended SNARE modulation / Acetylcholine inhibition (proposed Botox alternative) ~2–4 hours (topical) Not FDA-approved (cosmetic ingredient) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Expression wrinkles (dynamic lines); neuromuscular junction relaxation analog (topical) Typically 2–5% in cosmetic formulations Topical (creams, serums, eye patches) Extended Argireline with two additional amino acids. Claimed improved potency vs. Argireline. Minimal peer-reviewed efficacy data
Leuphasyl (Hexapeptide-11) Synthetic hexapeptide (Palmitoyl-Pro-Asn-Thr-Asn-Leu-Ala, matrix metalloproteinase inhibitor proposed) MMP inhibition (skin-matrix degradation prevention); collagen preservation ~2–3 hours (topical) Not FDA-approved (cosmetic ingredient) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Matrix preservation (anti-MMP); collagen/elastin fiber integrity; skin sagging prevention (proposed) Typically 2–4% in cosmetic formulations Topical (serums, firming creams) MMP-inhibitor design rationale. Alternative to collagen-upregulating peptides. Limited cosmetic industry data
Palmitoyl Tripeptide-1 (Pal-GHK) Synthetic tripeptide conjugated to palmitic acid (Pal-Gly-His-Lys, copper-chelating glycine-histidine-lysine) Copper chelation (collagen synthesis via Lox upregulation); wound healing reactivation ~1–2 hours (topical) Not FDA-approved (cosmetic ingredient, component of Matrixyl 3000) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Dermal collagen cross-linking; elastin remodeling; scar remodeling (proposed) Typically 1–2% in cosmetic formulations (as Matrixyl 3000 blend component) Topical (anti-aging serums, creams) Core component of Matrixyl and Matrixyl 3000. Copper-dependent mechanism. Palmitoyl modification enhances skin penetration
Palmitoyl Tetrapeptide-7 (Pal-GHKGQ) Synthetic tetrapeptide conjugated to palmitic acid (Pal-Gly-His-Lys-Gly-Gln, extended GHK variant with elastin-targeting residues) Elastin upregulation; integrin signaling activation (proposed); elastin-specific pathway ~1–3 hours (topical) Not FDA-approved (cosmetic ingredient, component of Matrixyl 3000) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Elastin remodeling (distinct from collagen pathway); skin elasticity and bounce; fine-line reduction (proposed) Typically 1–2% in cosmetic formulations (as Matrixyl 3000 blend component) Topical (anti-aging serums, firming creams) Extended GHK variant targeting elastin specifically. Synergistic with Palmitoyl Tripeptide-1 in Matrixyl 3000
Syn-Ake (Dipeptide Diethylaminobutyroyl Benzylamide Diacetate, Snake Venom Mimetic Peptide) Synthetic dipeptide-conjugate mimicking snake venom neurotoxins (synthetic neuro-blocking peptide) Neuromuscular junction analog blockade (topical snake venom mimic); acetylcholine inhibition ~2–4 hours (topical) Not FDA-approved (cosmetic ingredient) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Expression line relaxation (periorbital wrinkles); dynamic wrinkle reduction (snake venom analog mechanism topical) Typically 1–3% in cosmetic formulations Topical (eye creams, serums, patches) Snake venom analog mechanism. Branded as natural-origin alternative to botulinum toxin. Limited clinical efficacy studies
Acetyl Tetrapeptide-5 (SNAP-25 Mimic) Synthetic tetrapeptide (Ac-Glu-Glu-Met-Gln, acetylated SNARE domain fragment) SNAP-25 modulation (neuromuscular junction-like topical effect, proposed) ~1–3 hours (topical) Not FDA-approved (cosmetic ingredient) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Expression lines (wrinkle reduction, proposed Botox analog); muscle-relaxation topical effect Typically 2–5% in cosmetic formulations Topical (anti-wrinkle serums, creams) Short SNAP-25 fragment. Purported Botox alternative via topical neuromuscular effects. Minimal published efficacy data
Palmitoyl Hexapeptide-12 Synthetic hexapeptide conjugated to palmitic acid (Pal-containing; proprietary exact sequence variable by supplier) Broad dermal remodeling (collagen + elastin + proteoglycan synthesis proposed) ~2–3 hours (topical) Not FDA-approved (cosmetic ingredient, proprietary formulations) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Multi-target dermal remodeling (collagen, elastin, GAGs); hydration and firmness (proposed) Typically 1–3% in cosmetic formulations Topical (moisturizers, anti-aging serums) Extended hexapeptide with broader claimed targets than Tripeptide-1 or Tetrapeptide-7. Proprietary variations limit standardization
AHK-Cu (Copper Tripeptide: Ala-His-Lys + Cu²⁺) Synthetic tripeptide-copper complex (alanine-histidine-lysine chelated to Cu²⁺, GHK-Cu analog) Collagen synthesis (copper-dependent lysyl oxidase activation); similar mechanism to GHK-Cu topical ~1–2 hours (topical) Not FDA-approved (cosmetic ingredient) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Dermal collagen remodeling; anti-aging (collagen-dependent wrinkle reduction); scar appearance improvement Typically 0.5–2% in cosmetic formulations Topical (serums, creams; AHK-Cu generally topical only, unlike GHK-Cu) GHK-Cu alternative with alanine substitution. More stable copper complex than GHK-Cu in some formulations. Cosmetic-grade copper peptide
Tripeptide-29 (Proprietary Sequence, Collagen-Targeting Peptide) Synthetic tripeptide (exact sequence proprietary; collagen I/III targeting proposed) Collagen-specific upregulation (proprietary mechanism); dermal matrix support ~1–2 hours (topical) Not FDA-approved (cosmetic ingredient) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Collagen I and III upregulation; skin resilience and firmness (proposed); anti-sagging Typically 1–2% in cosmetic formulations Topical (anti-aging creams, serums) Proprietary peptide composition (exact sequence not published). Limited third-party efficacy studies

Summary and Key Takeaways

Acetyl tetrapeptide-5 (Eyeseryl) is the most mechanistically distinct compound in Cluster G — the only one targeting periorbital edema via capillary permeability reduction and anti-glycation rather than collagen synthesis or neuromuscular inhibition. The clinical evidence is a single manufacturer-sponsored study of 20 women with a 70% puffiness reduction headline that belongs in context alongside its study population characteristics and design limitations. The topical safety profile is good. The periorbital anatomy introduces specific safety considerations for microneedling and injection that are substantially more serious than equivalent concerns for other facial areas — the risk of vision loss from periorbital vascular compromise exists regardless of what compound is being injected.

  • Acetyl tetrapeptide-5 (Eyeseryl®, Lipotec/Lubrizol) is a synthetic tetrapeptide designed specifically for the periorbital area, targeting under-eye puffiness through two complementary mechanisms: capillary permeability reduction and anti-glycation.
  • It is the only Cluster G compound targeting edema — every other compound targets collagen synthesis or NMJ inhibition. The mechanism is genuinely distinct and fills a gap that collagen-stimulating peptides do not address.
  • Under-eye puffiness has multiple causes — only the edema and glycation components are addressable by this compound. Structural fat herniation, positional fluid, and allergic edema are not addressable by topical peptides regardless of evidence quality.
  • Primary clinical study: 20 women, 5% formulation, 60 days, profilometry. Reports 70% reduction in under-eye puffiness. Single manufacturer-sponsored study; not published as standalone peer-reviewed article in PubMed. Study population may over-represent the reversible edema component.
  • Topical application at 3–5% in properly formulated eye-area products is the evidence-supported route. Periorbital skin is thinner than other facial skin, improving penetration to target structures relative to equivalent concentrations elsewhere.
  • Periorbital microneedling requires specific technique modification (very shallow depth, appropriate device) and carries higher anatomical risk than facial microneedling elsewhere. Standard community protocols are not appropriate for this area.
  • Periorbital injection of any compound carries risk of serious adverse events including vision loss through ophthalmic artery compromise — this is an anatomical risk that exists regardless of the compound being injected. SC injection of acetyl tetrapeptide-5 near the eye has no defensible risk-benefit ratio.
  • WADA: not prohibited. Regulatory: cosmetic ingredient, not a drug.

The research moves fast. We read all of it so you don’t have to.

New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.

Subscribe to Peptidings Weekly

Selected References and Key Studies

  1. Lipotec technical dossier: Eyeseryl® (acetyl tetrapeptide-5). Clinical efficacy and safety data on file, Lubrizol Advanced Materials. Available at: lubrizol.com/personal-care
  2. Gorouhi F, Maibach HI. Role of topical peptides in preventing or treating aged skin. Int J Cosmet Sci. 2009;31(5):327–45. PMID 19624730
  3. Schagen SK. Topical peptide treatments with effective anti-aging results. Cosmetics. 2017;4(2):16. doi:10.3390/cosmetics4020016
  4. Ulrich P, Cerami A. Protein glycation, diabetes, and aging. Recent Prog Horm Res. 2001;56:1–21. PMID 11237208 — foundational AGE/glycation biology reference
  5. Sundaram H, et al. Topically applied physiologically balanced growth factors: a new paradigm of skin rejuvenation. J Drugs Dermatol. 2009;8(5 Suppl Skin):4–13. PMID 19492664 — periorbital skin context
  6. Dayan SH, et al. Overview of ATX-101 (deoxycholic acid injection): a nonsurgical approach for reduction of submental fat. Dermatol Surg. 2016;42(S1):S263–70. — periorbital vascular anatomy reference for injection risk context. PMID 26882893

Further Reading and References

Disclaimer

This article is produced for educational and research purposes only. Peptidings does not provide medical advice, diagnosis, or treatment recommendations. Nothing in this article should be interpreted as an endorsement of any cosmetic product, formulation, or delivery method.

Acetyl tetrapeptide-5 is a cosmetic ingredient, not an FDA-approved drug. It has not been evaluated by the FDA for safety or efficacy. Eyeseryl® is a registered trademark of Lubrizol Advanced Materials (via Lipotec). The periorbital area requires additional care with any topical or invasive treatment — consult a qualified healthcare professional before any non-topical application in or near the eye area.

All citations link to primary sources where available. Manufacturer-sponsored studies are identified as such. Readers are encouraged to evaluate the evidence independently.

Scroll to Top